ArticleCureus2025
Clinicopathologic Characteristics and Treatment Outcomes of Triple-Negative Breast Cancer at a Latin American Tertiary Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, represents a biologically aggressive subtype, and is frequently diagnosed at advanced stages. Regional data on its presentation and outcomes remain limited in Latin America. We evaluated the clinicopathologic features, treatment patterns, and survival of women with TNBC managed at a tertiary referral center. Methods A retrospective descriptive study was conducted of adult patients with pathologically confirmed TNBC who initiated and completed treatment at San Ignacio University Hospital, Bogotá, between August 2017 and June 2023. We reviewed medical records for demographic, tumor, and treatment variables, and we assessed patient responses to neoadjuvant chemotherapy (NAC) with the residual cancer burden (RCB) system. We used the Kaplan-Meier method to generate recurrence-free survival curves and compared survival in the subjects with and without pathological complete response. Results Of 1,083 breast cancer cases, 125 (11.5 %) were identified as TNBC. Most patients presented with stage II-III disease (104/125, 83.2 %) and node positivity (68/125, 54.4 %). NAC was administered to 90/125 women (72%); anthracycline-/taxane-based regimens predominated. Pathologic complete response after NAC occurred in 25/88 cases (28.4%). Forty-six patients had breast-conserving surgery (39.7%), whereas 70 patients (60.3%) underwent mastectomy. The estimated three-year recurrence/progression-free survival (PFS) was 79.4% [95% confidence interval (CI): 71.5%-88.2%]. The estimated three-year overall survival is 74.4% (95% CI: 66%-83.9%). Limited access to germline testing, advanced molecular profiling, and newer systemic agents was evident. Conclusions Within this Latin-American center, TNBC was infrequent yet predominantly diagnosed at advanced stages and carried substantial risks of relapse and death. Earlier detection, broader availability of genetic and molecular testing, and equitable access to emerging targeted and immune-based therapies are essential to improve outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.